Northwest Biotherapeutics brain cancer vaccine increases time to disease progression in phase 1 trial

By Lisa Kerner

Erie, Pa., May 23 - Northwest Biotherapeutics said six of the 10 patients with Glioblastoma multiforme (GBM) in its phase 1 trial of the cancer vaccine DCVax-Brain are still alive, with a median survival of more than 22 months.

Five of the 10 patients continue to show no signs of cancer recurrence, while all but one of the patients surpassed the historical median time to progression of eight months.

The vaccine uses autologous dendritic cells pulsed with tumor antigens to safely stimulate antitumor immune responses, according to a company news release.

The data was presented at the 12th Annual Meeting of the International Society for Cellular Therapy in Berlin.

GBM's typical median times to progression and death are about eigth and 15 months, respectively. Primary therapy includes surgery followed by radiotherapy and concurrent chemotherapy.

Located in Bothell, Wash., Northwest develops immunotherapy products to treat cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.